Kamada Reports Record Top- and Bottom-line 2025 Financial Results and Affirms 2026 Guidance Representing Continued Double-Digit Organic Profitable Growth

Core Viewpoint - Kamada Ltd. reported strong financial performance for 2025, achieving record revenues and adjusted EBITDA, and is optimistic about continued growth in 2026 with affirmed guidance [2][5][10]. Financial Performance - Total revenues for 2025 were $180.5 million, a 12% increase from $161.0 million in 2024 [6]. - Adjusted EBITDA for 2025 was $42.0 million, reflecting a 23% increase from $34.1 million in 2024 [5][13]. - Net income for 2025 was $20.2 million, a 40% increase compared to $14.5 million in 2024 [5][6]. - The company generated $25.5 million in cash from operating activities in 2025, contributing to a cash position of $75.5 million at year-end [2][5]. 2026 Guidance - Kamada affirmed its 2026 annual guidance, projecting revenues between $200 million and $205 million, and adjusted EBITDA between $50 million and $53 million, representing year-over-year growth of 13% and 23% respectively [2][10][19]. Strategic Focus - The company plans to expand its commercial product portfolio, invest in the commercialization of FDA-approved specialty plasma-derived products, and grow its Distribution segment through new biosimilar products [3][19]. - Kamada aims to enhance plasma collection operations to support revenue growth and reduce costs [3][19]. - The company is also looking to secure new business development and M&A transactions to accelerate profitable growth and enrich its product portfolio [5][19]. Dividend Policy - Kamada adopted an annual cash dividend policy, declaring a cash dividend of $0.25 per share, totaling approximately $14.4 million, to be paid on April 6, 2026 [5][14]. Recent Developments - The company announced a $10 million to $14 million extension of an existing tender with Canadian Blood Services for the supply of specialty plasma-derived products [14]. - Kamada discontinued its Phase 3 Inhaled AAT clinical trial [14].